• Home
  • The Right Molecule
  • The Right Indication
  • The Right Study Design
  • Our Team
  • Intellectual Property
  • Clinical Milestones
  • Contact Us

Our Approach

The Right Molecule

The Right Study Design

The Right Indication

Our lead asset, STX-101, is a novel 

5-HT3 Receptor Partial Agonist offering a clinically validated mechanism that ensures a safer therapeutic profile and avoids the Black Box safety limitations of full 5-HT3R antagonists.

Learn More

The Right Indication

The Right Study Design

The Right Indication

Low Anterior Resection Syndrome (LARS) is a debilitating life-long post-surgical functional gastrointestinal disorder in rectal cancer survivors with no approved therapy, representing a $2B+ U.S. market opportunity. Two positive randomized trials demonstrate the efficacy of full 5-HT3R antagonists in LARS.

Learn More

The Right Study Design

The Right Study Design

The Right Study Design

An enriched patient-centric design isolates the drug effect by using a decentralized clinical trial and engagement platform that normalizes patients to the placebo effect and supportive care prior to randomization.

Learn More

Copyright © 2025 Serotonix, LLC - All Rights Reserved

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept